Search Videos by Topic or Participant
Browse by Series:

Intricacies of Checkpoint Inhibition in NSCLC

Panelists: Roy S. Herbst, MD, PhD, Yale; Mark A. Socinski, MD, University of Pittsburgh;Thomas E. Stinchcombe, MD, UNC; Anne S. Tsao, MD, MD Ande
Published: Tuesday, Mar 24, 2015
For High-Definition, Click
Immune checkpoint inhibitors have demonstrated high levels of antitumor activity in patients with non-small cell lung cancer (NSCLC). Despite this, excitement over efficacy should not overshadow the potential side effects associated with these therapies, including autoimmunity, notes Anne S. Tsao, MD.

A few of the more critical side effects associated with PD-1 inhibition include colitis, fatigue, and pneumonitis. While diarrhea is a common toxicity of many treatments, it is more serious with the immunotherapies, as it is often coupled with colitis, Tsao suggests. Steroids could represent a potential treatment for many of these side effects, suggests Mark A. Socinski, MD. 

Pseudo-progression, which is characterized by tumor growth followed by sustained shrinkage, represents a unique phenomenon associated with immune checkpoint inhibitors, notes Heather A. Wakelee, MD. This should be considered when assessing a patient for response. In general, scans should be assessed in addition to symptoms and other patient characteristics.

Various patient and tumor characteristics, including smoking status, histologies, and mutations, are associated with responses to immunotherapy, explains Roy S. Herbst, MD. In contrast to the lack of success with many other current therapies, studies are seeing activity with immunotherapy in patients with squamous cell NSCLC, smokers, and in tumors that harbor KRAS mutations.
 
Slider Left
Slider Right
For High-Definition, Click
Immune checkpoint inhibitors have demonstrated high levels of antitumor activity in patients with non-small cell lung cancer (NSCLC). Despite this, excitement over efficacy should not overshadow the potential side effects associated with these therapies, including autoimmunity, notes Anne S. Tsao, MD.

A few of the more critical side effects associated with PD-1 inhibition include colitis, fatigue, and pneumonitis. While diarrhea is a common toxicity of many treatments, it is more serious with the immunotherapies, as it is often coupled with colitis, Tsao suggests. Steroids could represent a potential treatment for many of these side effects, suggests Mark A. Socinski, MD. 

Pseudo-progression, which is characterized by tumor growth followed by sustained shrinkage, represents a unique phenomenon associated with immune checkpoint inhibitors, notes Heather A. Wakelee, MD. This should be considered when assessing a patient for response. In general, scans should be assessed in addition to symptoms and other patient characteristics.

Various patient and tumor characteristics, including smoking status, histologies, and mutations, are associated with responses to immunotherapy, explains Roy S. Herbst, MD. In contrast to the lack of success with many other current therapies, studies are seeing activity with immunotherapy in patients with squamous cell NSCLC, smokers, and in tumors that harbor KRAS mutations.
 
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x